$50.07 +$1.51 (+3.11%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $49.35 -1.44%
开盘$48.98
昨收$48.56
当日区间$48.41 – $50.27
成交量1.24M
市值$4.86B
市盈率（TTM）–
股息率–
CRSP 相关新闻
匹配 CRISPR Therapeutics 或代码 CRSP 的头条新闻，按最新排序。
- Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Raises Target Price to $55 正面
- BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82 负面
- A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $60 to $110
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
- Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76
- H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
- Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
- William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
- Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $55
- BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $83
- Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $110
- Morgan Stanley Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $60
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
- Morgan Stanley Upgrades CRISPR Therapeutics(CRSP.US) to Hold Rating, Raises Target Price to $60 正面
- Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $75
暂无评论——快来第一个聊聊 CRSP。
登录后参与讨论。